ClinicalTrials.gg
CompletedNCT03468985Updated Oct 17, 2023Results posted

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

A Phase 2 interventional study of Cabozantinib and Ipilimumab in Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma and Stage IV Lung Non-Small Cell Cancer AJCC v7, sponsored by National Cancer Institute (NCI). Completed at 468 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This partially randomized phase II trial studies how well nivolumab, cabozantinib s-malate, and ipilimumab work in treating patients with stage IV non-small cell lung cancer that has come back. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab, cabozantinib s-malate, and ipilimumab may work better than cabozantinib s-malate alone in treating patients with stage IV non-small cell lung cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To demonstrate whether combination therapy of nivolumab and cabozantinib s-malate (cabozantinib), or of nivolumab and cabozantinib, and ipilimumab as compared to nivolumab alone, extends progression-free survival (PFS) for this patient population with non-squamous non-small cell lung cancer (NSCLC).

SECONDARY OBJECTIVES:

I. To estimate the overall survival for each arm of the trial. II. To estimate the best overall response rate for each arm of the trial. III. To estimate the progression free survival of the targeted therapy arm of the trial.

IV. To describe the toxicity profile of monotherapy with nivolumab, and the combination of nivolumab and cabozantinib, and the combination of nivolumab and cabozantinib and ipilimumab, in this patient population with non-squamous NSCLC.

CORRELATIVE OBJECTIVES:

I. To adjust progression free survival for each arm based on PD-L1 tumor status.

IMAGING OBJECTIVES:

I. To describe time point tumor response assessment, overall best response and progression-free survival using the conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and the exploratory uni-dimensional immune response criteria (iRRC) and the imaging (i)RECIST criteria with all measurements performed by the central review.

II. To compare RECIST 1.1 imaging response assessment measurements (time point response assessment and overall best response) assess by site study personnel to those performed by central review.

EXPLORATORY TOBACCO USE OBJECTIVES:

I. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported cancer-treatment toxicity (adverse events (both clinical and hematologic) and dose modifications).

II. To determine the effects of tobacco on patient-reported physical symptoms and psychological symptoms.

III. To examine quitting behaviors and behavioral counseling/support and cessation medication utilization.

IV. To explore the effect of tobacco use and exposure on treatment duration, relative dose intensity, and therapeutic benefit.

OUTLINE: Patients are randomized to 1 of 3 arms. Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement are assigned to Arm T.

ARM A: Patients receive nivolumab at 480 mg intravenously (IV) over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive nivolumab at 480 mg IV over 60 minutes on day 1 and cabozantinib s-malate at 40 mg orally (PO) daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM C: Patients receive nivolumab at 480 mg IV over 60 minutes on day 1, cabozantinib s-malate at 40 mg PO daily on days 1-28, and ipilimumab at 1 mg/kg IV over 90 minutes every 8 weeks. Cycles for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM T: Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab at 480 mg IV over 60 minutes on day 1 and cabozantinib s-malate at 40 mg PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 5 years.

02

Conditions studied

  • Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
  • Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
  • Stage IV Lung Non-Small Cell Cancer AJCC v7

Keywords

  • Nivolumab
  • Cabozantinib
  • Ipilimumab
  • NSCLC
03

In context

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Step 0):

  • Patients with tumors with the following molecular alterations must submit testing results via Medidata Rave to determine eligibility to Arm T; the study chair, co-chair, biology co-chair, or a delegate must review the molecular testing and agree that the testing meets one of the molecular eligibility criteria below:

    • ROS1 gene rearrangement by fluorescence in situ hybridization (FISH) or deoxyribonucleic acid (DNA) analysis (may have progressed on prior crizotinib therapy)
    • MET exon 14 splice mutations on DNA analysis (may have progressed on prior crizotinib therapy)
    • MET high amplification by FISH or DNA analysis or other MET mutations predicted to be sensitive to MET inhibitor (no prior targeted therapy allowed)
    • RET gene rearrangement by FISH or DNA analysis (no prior targeted therapy allowed)

      • Institutions will be notified of the patient's eligibility status for Arm T within two (2) business days of submission of the molecular testing reports
      • If patients do not have tumors with the above molecular alterations noted proceed directly to step 1

Inclusion Criteria (Step 1):

  • For patients with known molecular alterations, institution has been notified that patient is deemed eligible for Arm T per review of molecular testing reports
  • confirmed non-squamous non-small cell lung carcinoma (NSCLC)
  • Stage IV disease (includes M1a, M1b, or recurrent disease), according to the 7th edition of the lung cancer tumor, node, and (TNM) classification system
  • Predominant non-squamous histology (patients with NSCLC not otherwise specified [NOS] are eligible); mixed tumors will be categorized by the predominant cell type; if small cell elements are present the patient is ineligible
  • Tumors must be tested and known negative for EGFR tyrosine kinase inhibitor (TKI) sensitizing mutations (EGFR exon 19 deletions, L858R, L861Q, G719X) and ALK gene rearrangements by routine Clinical Laboratory Improvement Act (CLIA)-certified clinical testing methods; negative circulating tumor DNA results alone are not acceptable; prior testing for tumor status is not required
  • Patients must have progressed radiographically following platinum-based chemotherapy, no additional lines of therapy are permitted

    • NOTE: Prior chemotherapy for early stage disease does not count as one line of therapy if 12 months or greater elapsed between completion of adjuvant therapy and initiation of first-line systemic therapy; if less than 12 months elapsed, adjuvant chemotherapy counts as one line of therapy
    • Exception for targeted therapy sub-study (Arm T): At least one line of prior chemotherapy or targeted therapy is required, but there is no limit on number of prior treatments
  • Patients must have as defined by v. 1.1 criteria; baseline measurements and evaluation of all sites of disease must be obtained within 4 weeks prior to registration
  • Any prior chemotherapy (based on administration schedule) must have been completed in greater than or equal to the following times prior to registration:

    • Chemotherapy/ targeted oral therapy administered in a daily or weekly schedule must be completed >= 1 week prior to registration;
    • Any chemotherapy administered in an every 2 week or greater schedule must be completed >= 2 weeks prior to registration
    • Additionally, patients should be recovered to equal to or less than grade 1 toxicities related to any prior treatment, unless adverse event (AE)(s) are clinically nonsignificant and/or stable on supportive therapy
  • Patients with no known must have baseline brain imaging within 12 weeks prior to study registration not demonstrating brain metastases OR patients with known brain metastases must have baseline brain imaging within 4 weeks prior to study registration and meet all of the following criteria:

    • Have completed treatment to all symptomatic brain metastases (with whole brain radiation or radiosurgery) >= 4 weeks prior to registration, or have undergone complete neurosurgical resection >= 3 months prior to registration
    • Be clinically stable from brain metastases at time of screening, if no treatment was administered
    • Known is not allowed
  • Patients must have (ECOG) performance status 0-1
  • Patients must have anticipated greater than 3 months
  • >= 1,500/mm\^3 (within 2 weeks prior to registration)
  • >= 100,000/mm\^3 (within 2 weeks prior to registration)
  • >= 9 g/dL (within 2 weeks prior to registration)
  • Subject has (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) test =\< 1.3 x the laboratory (ULN) (within 2 weeks prior to registration)
  • Total =\< 1.5 x ULN (within 2 weeks prior to registration)
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =\< 3 x ULN (within 2 weeks prior to registration)
  • Serum albumin >= 2.8 g/dL (within 2 weeks prior to registration)
  • Serum calcium (absolute or albumin corrected), magnesium and potassium >= lower limit of normal (LLN) (within 2 weeks prior to registration)

    • NOTE: serum calcium, magnesium and potassium can be replaced if values are below LLN
  • Creatinine =\< 1.5 x ULN or calculated ( formula) or measured creatinine clearance >= 50 mL/min/1.73 m\^2 (normalized to body surface area [BSA]) for patients with creatinine levels greater than 1.5 times the institutional normal (within 2 weeks prior to registration)
  • Screening urine dipstick must equal 0 or "trace"; if urine dipstick results are >= 1+, or if dipstick was not performed, calculation of urine protein creatinine (UPC) is required and patients must have a UPC ratio =\< 1 to participate in the study (within 2 weeks prior to registration)
  • Patients must have interval calculated by the Fridericia formula (QTcF) =\< 500 ms within 28 days before registration
  • Patients must be able to swallow tablets

    • All females of must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy
    • A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must use an accepted and effective method of or abstain from sexual intercourse for at least one week prior to the start of treatment, and continue for 5 months after the last dose of protocol treatment for women of childbearing potential and 7 months after the last dose of protocol treatment for males who are sexually active with WOCBP

Exclusion Criteria (Step 1):

  • Small cell elements are present
  • Prior anti-MET therapy such as crizotinib or cabozantinib, or PD-1/PD-L1 immune checkpoint inhibitor therapy (such as nivolumab, pembrolizumab, atezolizumab) or CTLA4 inhibitor therapy (such as ipilimumab); prior allergic reaction to small molecule tyrosine kinase inhibitors or monoclonal antibodies

    • Exception for targeted therapy sub-study (Arm T): Prior crizotinib may be allowed depending on the gene alteration
  • Prior radiation therapy for bone metastasis within 2 weeks; any other radiation therapy within 4 weeks prior to registration
  • Known leptomeningeal disease
  • Impaired decision-making capacity (IDMC)
  • Clinically-significant gastrointestinal bleeding within 6 months prior to registration
  • Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months prior to registration
  • Drug induced pneumonitis within 3 months prior to registration
  • Signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
  • Radiographic evidence of cavitating pulmonary lesion(s)
  • Tumor invading any major blood vessels
  • Evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or mainstem endobronchial tumor within 28 days before the first dose of cabozantinib
  • Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel); allowed anticoagulants are the following:

    • Low-dose aspirin for cardioprotection (per local applicable guidelines) is permitted
    • Low molecular weight heparins (LMWH) or unfractionated heparin is permitted
    • Anticoagulation with therapeutic doses of LMWH is allowed in subjects without known brain metastases who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no hemorrhagic complications from the anticoagulation regimen or the tumor
  • Concomitant treatment of strong inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's wort)
  • Cardiovascular disorders including:

    • Congestive heart failure (CHF): (NYHA) class III (moderate) or class IV (severe) at the time of screening
    • Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic, or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days prior to registration
    • Any of the following within 6 months prior to registration:

      • Unstable angina pectoris
      • Clinically-significant cardiac arrhythmias
      • Stroke (including [TIA], or other ischemic event)
      • Myocardial infarction
  • Gastrointestinal disorders associated with a high risk of perforation or fistula formation within 3 months prior to registration:

    • Active peptic ulcer disease
    • Inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis
    • Known malabsorption syndrome
    • Bowel obstruction or gastric outlet obstruction
    • Percutaneous endoscopic gastrostomy (PEG) tube placement
  • Gastrointestinal disorders associated with a high risk of perforation or fistula formation within 6 months prior to registration:

    • Abdominal fistula
    • Gastrointestinal perforation
    • Intra-abdominal abscess; Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months prior to registration
  • Any of the following conditions:

    • Grade 3 or greater infection, or infection requiring intravenous systemic treatment within 28 days prior to registration; patients should be off antibiotics at the time of registration.
    • Serious non-healing wound/ulcer/bone fracture within 28 days prior to registration
    • History of organ transplant
    • Concurrent symptomatic untreated hypothyroidism within 7 days prior to registration
    • History of surgery as follows:

      • Major surgery (as an example, surgery requiring anesthesia and a > 24 hour hospital stay) within 3 months prior to registration, with wound healing at least 28 days prior to registration
      • Minor surgery within 28 days prior to registration with complete wound healing at least 10 days prior to registration
      • Minor procedures within 7 days prior to registration such as thoracentesis, paracentesis, or 18 g or smaller needle of tumor
      • Patients with clinically relevant ongoing complications from prior surgery are not eligible
  • Currently active other which require systemic treatment
  • A condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =\< 10 mg daily prednisone equivalents are permitted in the absence of active disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if \< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type reaction caused by contact allergen) is permitted
  • Active autoimmune disease or known history of autoimmune disease for which recurrence may affect vital organ function or require immune suppressive treatment including systemic corticosteroids; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, autoimmune hepatitis; patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease; patients with vitiligo, endocrine deficiencies including type I diabetes mellitus or thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
  • Ongoing major illness or psychosocial issues that would limit compliance with the protocol
  • Pregnant or breast-feeding
  • Patients with known (HIV) disease taking antiretroviral therapy are excluded because there are no safety data with the combination of antiretroviral therapy and cabozantinib or ipilimumab or nivolumab with ipilimumab

    • Patients with known chronic active (defined as a positive hepatitis B surface antigen and/or hepatitis B viral load in the last
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Active comparator
    Arm A (nivolumab)

    Patients receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Biological: Nivolumab

  • Experimental
    Arm B (nivolumab, cabozantinib)

    Patients receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Cabozantinib · Biological: Nivolumab

  • Experimental
    Arm C (nivolumab, cabozantinib, ipilimumab)

    Patients receive nivolumab IV over 60 minutes on day 1, cabozantinib s-malate PO daily on days 1-28, and ipilimumab IV over 90 minutes every 8 weeks. Cycles for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Cabozantinib · Biological: Ipilimumab · Biological: Nivolumab

  • Experimental
    Arm T (Targeted cohort; nivolumab, cabozantinib)

    Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Cabozantinib · Biological: Nivolumab

Interventions

  • Given PO

    Also known as: Cabozantinib s-malate, XL-184, EXEL-7184, EXEL-02977184, Cabometyx®

  • BiologicalIpilimumab

    Given IV

    Also known as: Anti-CTLA-4 monoclonal antibody, MDX-010, Yervoy

  • BiologicalNivolumab

    Given IV

    Also known as: BMS-936558, MDX1106

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival is defined as time from randomization to documented disease progression or death from any cause, whichever occurs first. Progression is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions and/or at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS will be estimated using the Kaplan-Meier method.

    Time frame: Every 3 months up to 4 years and 2 months

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as time from randomization to death or date last known alive.

    Time frame: Every 3 months up to 4 years and 2 months

  2. Best Overall Response

    Best overall response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Response is defined as either complete response (CR) or partial response (PR). Complete response is defined as disappearance of all lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. For Arm T patients, to be assigned a status of CR or PR, changes in tumor measurements must be confirmed by repeat assessments performed no less than four weeks after the criteria for response are first met. Arm A, B, and C patients do not require confirmation scans for CR or PR.

    Time frame: Every 3 months up to 4 years and 2 months

Other outcomes

  1. Progression-free Survival (PFS) by Programmed Death-ligand 1 (PD-L1) Status

    Progression-free survival is defined as time from randomization to documented disease progression or death from any cause, whichever occurs first. Progression is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions and/or at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS will be estimated using the Kaplan-Meier method.

    Time frame: Every 3 months for 5 years

  2. The Distribution of Best Overall Response by RECIST 1.1 Criteria, Uni-dimensional Immune Response Criteria (iRRC) and Immune Response Evaluation Criteria in Solid Tumors (iRECIST) Criteria

    Best overall response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria: Response is defined as either complete response (CR) or partial response (PR). Complete response is defined as disappearance of all lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Response by iRRC is defined as per RECIST1.1. Measurements of iRECIST response will be performed as described by Seymour et al with time point and over all response assessments categorized as immune complete response (iCR), immune partial response (iPR), immune stable disease (iSD), immune unconfirmed progressive disease (iUPD) and confirmed progressive disease (iCPD).

    Time frame: Every 3 months for 5 years

  3. Response Per RECIST1.1 Performed by Central Review and by Site Study Personnel

    Best overall response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria: Response is defined as either complete response (CR) or partial response (PR). Complete response is defined as disappearance of all lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Every 3 months for 5 years

  4. Effects of Tobacco on Provider-reported Cancer-treatment Toxicity and Dose Modifications

    A combined analysis of the data from the selected Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN) trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report.

    Time frame: Assessed every 4 weeks until 30 days after treatment completion, up to 5 years

  5. Effects of Tobacco on Patient-reported Physical Symptoms and Psychological Symptoms

    A combined analysis of the data from the selected ECOG-ACRIN trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report. Psychological Symptom Assessment: Anxiety \& Depression: (The Patient Reported Outcomes Measurement Information System (PROMIS®)). The 4-item Short Form PROMIS® for anxiety and depression will be administered. Score ranges between 4 and 20. Higher scores indicate more anxiety/depression. Physical Symptom Assessment by Functional Assessment of Chronic Illness Therapy (FACIT): Six symptom items (general pain, fatigue, nausea, cough, sleep difficulties, shortness of breath) from FACIT will be used for evaluation. Score ranges between 5 and 20. Higher scores indicate higher shame.

    Time frame: Baseline, 3 months and 6 months

  6. Assessment of Quitting Behaviors, Behavioral Counseling/Support and Cessation Medication Utilization

    A combined analysis of the data from the selected ECOG-ACRIN trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report.

    Time frame: Baseline, 3 months and 6 months

  7. Effects of Tobacco Use and Exposure on Treatment Duration, Relative Dose Intensity, and Therapeutic Benefit

    A combined analysis of the data from the selected ECOG-ACRIN trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report.

    Time frame: Assessed every 3 months for 5 years

07

Results

Posted Feb 8, 2023

Participant flow

The study was activated on March 1, 2018 and closed on May 31, 2019 for a total of 3 patients enrolled on this study. Patients were randomized to 1 of 3 arms (arms A, B and C). Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement were assigned to Arm T.

Participant flow — Overall Study
MilestoneArm A (Nivolumab)Arm B (Nivolumab, Cabozantinib)Arm C (Nivolumab, Cabozantinib, Ipilimumab)Arm T (Targeted Cohort; Nivolumab, Cabozantinib)
Started0201
Completed0000
Not completed0201
Withdrew: Adverse event0200
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression-free survival is defined as time from randomization to documented disease progression or death from any cause, whichever occurs first. Progression is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions and/or at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS will be estimated using the Kaplan-Meier method.

Time frame:
Every 3 months up to 4 years and 2 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsArm A (Nivolumab)Arm B (Nivolumab, Cabozantinib)Arm C (Nivolumab, Cabozantinib, Ipilimumab)Arm T (Targeted Cohort; Nivolumab, Cabozantinib)
Progression-free Survival (PFS)—6.35 (3.3 to NA)—14.3 (NA to NA)
SecondaryOverall Survival

Overall survival is defined as time from randomization to death or date last known alive.

Time frame:
Every 3 months up to 4 years and 2 months
Reported as:
Median · months
Overall Survival
monthsArm A (Nivolumab)Arm B (Nivolumab, Cabozantinib)Arm C (Nivolumab, Cabozantinib, Ipilimumab)Arm T (Targeted Cohort; Nivolumab, Cabozantinib)
Overall Survival—11.85 (11.7 to NA)—NA (NA to NA)
SecondaryBest Overall Response

Best overall response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Response is defined as either complete response (CR) or partial response (PR). Complete response is defined as disappearance of all lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. For Arm T patients, to be assigned a status of CR or PR, changes in tumor measurements must be confirmed by repeat assessments performed no less than four weeks after the criteria for response are first met. Arm A, B, and C patients do not require confirmation scans for CR or PR.

Time frame:
Every 3 months up to 4 years and 2 months
Reported as:
Count of participants · Participants
Best Overall Response
ParticipantsArm A (Nivolumab)Arm B (Nivolumab, Cabozantinib)Arm C (Nivolumab, Cabozantinib, Ipilimumab)Arm T (Targeted Cohort; Nivolumab, Cabozantinib)
Response (CR or PR)—0—0
No Response (Other)—2—1
Other pre-specifiedProgression-free Survival (PFS) by Programmed Death-ligand 1 (PD-L1) Status

Progression-free survival is defined as time from randomization to documented disease progression or death from any cause, whichever occurs first. Progression is defined as appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions and/or at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS will be estimated using the Kaplan-Meier method.

Time frame:
Every 3 months for 5 years

Results for this outcome have not been posted.

Other pre-specifiedThe Distribution of Best Overall Response by RECIST 1.1 Criteria, Uni-dimensional Immune Response Criteria (iRRC) and Immune Response Evaluation Criteria in Solid Tumors (iRECIST) Criteria

Best overall response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria: Response is defined as either complete response (CR) or partial response (PR). Complete response is defined as disappearance of all lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Response by iRRC is defined as per RECIST1.1. Measurements of iRECIST response will be performed as described by Seymour et al with time point and over all response assessments categorized as immune complete response (iCR), immune partial response (iPR), immune stable disease (iSD), immune unconfirmed progressive disease (iUPD) and confirmed progressive disease (iCPD).

Time frame:
Every 3 months for 5 years

Results for this outcome have not been posted.

Other pre-specifiedResponse Per RECIST1.1 Performed by Central Review and by Site Study Personnel

Best overall response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria: Response is defined as either complete response (CR) or partial response (PR). Complete response is defined as disappearance of all lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Every 3 months for 5 years

Results for this outcome have not been posted.

Other pre-specifiedEffects of Tobacco on Provider-reported Cancer-treatment Toxicity and Dose Modifications

A combined analysis of the data from the selected Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN) trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report.

Time frame:
Assessed every 4 weeks until 30 days after treatment completion, up to 5 years

Results for this outcome have not been posted.

Other pre-specifiedEffects of Tobacco on Patient-reported Physical Symptoms and Psychological Symptoms

A combined analysis of the data from the selected ECOG-ACRIN trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report. Psychological Symptom Assessment: Anxiety \& Depression: (The Patient Reported Outcomes Measurement Information System (PROMIS®)). The 4-item Short Form PROMIS® for anxiety and depression will be administered. Score ranges between 4 and 20. Higher scores indicate more anxiety/depression. Physical Symptom Assessment by Functional Assessment of Chronic Illness Therapy (FACIT): Six symptom items (general pain, fatigue, nausea, cough, sleep difficulties, shortness of breath) from FACIT will be used for evaluation. Score ranges between 5 and 20. Higher scores indicate higher shame.

Time frame:
Baseline, 3 months and 6 months

Results for this outcome have not been posted.

Other pre-specifiedAssessment of Quitting Behaviors, Behavioral Counseling/Support and Cessation Medication Utilization

A combined analysis of the data from the selected ECOG-ACRIN trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report.

Time frame:
Baseline, 3 months and 6 months

Results for this outcome have not been posted.

Other pre-specifiedEffects of Tobacco Use and Exposure on Treatment Duration, Relative Dose Intensity, and Therapeutic Benefit

A combined analysis of the data from the selected ECOG-ACRIN trials is planned. Data collected from the tobacco use assessment in each parent study will not be analyzed and reported in the clinical study report.

Time frame:
Assessed every 3 months for 5 years

Results for this outcome have not been posted.

Adverse events

Collected over Assessed every 4 weeks while on treatment and for 30 days after the end of treatment, up to 4 years and 2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A (Nivolumab)———
Arm B (Nivolumab, Cabozantinib)2/2 (100%)2/2 (100%)2/2 (100%)
Arm C (Nivolumab, Cabozantinib, Ipilimumab)———
Arm T (Targeted Cohort; Nivolumab, Cabozantinib)0/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventArm A (Nivolumab)Arm B (Nivolumab, Cabozantinib)Arm C (Nivolumab, Cabozantinib, Ipilimumab)Arm T (Targeted Cohort; Nivolumab, Cabozantinib)
FatigueGeneral disorders—0/2—1/1
Aspartate aminotransferase increasedInvestigations—2/2—0/1
Neutrophil count decreasedInvestigations—0/2—1/1
ArthralgiaMusculoskeletal and connective tissue disorders—0/2—1/1
Alanine aminotransferase increasedInvestigations—1/2—0/1
Lymphocyte count decreasedInvestigations—1/2—0/1
HypokalemiaMetabolism and nutrition disorders—1/2—0/1
HyponatremiaMetabolism and nutrition disorders—1/2—0/1
ArthritisMusculoskeletal and connective tissue disorders—1/2—0/1
HypertensionVascular disorders—1/2—0/1
Most frequent other events
Showing 10 of 28
Most frequent other events
EventArm A (Nivolumab)Arm B (Nivolumab, Cabozantinib)Arm C (Nivolumab, Cabozantinib, Ipilimumab)Arm T (Targeted Cohort; Nivolumab, Cabozantinib)
DiarrheaGastrointestinal disorders—2/2—0/1
Dry mouthGastrointestinal disorders—0/2—1/1
Mucositis oralGastrointestinal disorders—1/2—1/1
NauseaGastrointestinal disorders—2/2—0/1
FatigueGeneral disorders—2/2—0/1
Alanine aminotransferase increasedInvestigations—2/2—0/1
Blood bilirubin increasedInvestigations—2/2—0/1
Weight lossInvestigations—1/2—1/1
Rash maculo-papularSkin and subcutaneous tissue disorders—0/2—1/1
Endocrine disorders - Other, specifyEndocrine disorders—1/2—0/1

Baseline characteristics

All patients enrolled are included in this analysis.

Age, Continuous
Age, Continuous(years)Arm A (Nivolumab)Arm B (Nivolumab, Cabozantinib)Arm C (Nivolumab, Cabozantinib, Ipilimumab)Arm T (Targeted Cohort; Nivolumab, Cabozantinib)Total
Median—78 (75 to 81)—53 (53 to 53)75 (53 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Arm A (Nivolumab)Arm B (Nivolumab, Cabozantinib)Arm C (Nivolumab, Cabozantinib, Ipilimumab)Arm T (Targeted Cohort; Nivolumab, Cabozantinib)Total
Female—2—13
Male—0—00
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A (Nivolumab)Arm B (Nivolumab, Cabozantinib)Arm C (Nivolumab, Cabozantinib, Ipilimumab)Arm T (Targeted Cohort; Nivolumab, Cabozantinib)Total
Hispanic or Latino—0—00
Not Hispanic or Latino—1—12
Unknown or Not Reported—1—01
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A (Nivolumab)Arm B (Nivolumab, Cabozantinib)Arm C (Nivolumab, Cabozantinib, Ipilimumab)Arm T (Targeted Cohort; Nivolumab, Cabozantinib)Total
American Indian or Alaska Native—0—00
Asian—0—00
Native Hawaiian or Other Pacific Islander—0—00
Black or African American—0—00
White—2—13
More than one race—0—00
Unknown or Not Reported—0—00
08

Study locations

468 sites
  • Anchorage Associates in Radiation Medicine
    Anchorage, Alaska 98508, United States
  • Alaska Breast Care and Surgery LLC
    Anchorage, Alaska 99508, United States
  • Alaska Oncology and Hematology LLC
    Anchorage, Alaska 99508, United States
  • Alaska Women's Cancer Care
    Anchorage, Alaska 99508, United States
  • Anchorage Oncology Centre
    Anchorage, Alaska 99508, United States
  • Katmai Oncology Group
    Anchorage, Alaska 99508, United States
  • Providence Alaska Medical Center
    Anchorage, Alaska 99508, United States
  • CHI Saint Vincent Cancer Center Hot Springs
    Hot Springs, Arkansas 71913, United States
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
    Jonesboro, Arkansas 72401, United States
  • PCR Oncology
    Arroyo Grande, California 93420, United States
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center
    Burbank, California 91505, United States
  • Penrose-Saint Francis Healthcare
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer Centers-Penrose
    Colorado Springs, Colorado 80907, United States
  • Porter Adventist Hospital
    Denver, Colorado 80210, United States
  • Mercy Medical Center
    Durango, Colorado 81301, United States
  • Southwest Oncology PC
    Durango, Colorado 81301, United States
  • Mountain Blue Cancer Care Center
    Golden, Colorado 80401, United States
  • Rocky Mountain Cancer Centers-Lakewood
    Lakewood, Colorado 80228, United States
  • Saint Anthony Hospital
    Lakewood, Colorado 80228, United States
  • Littleton Adventist Hospital
    Littleton, Colorado 80122, United States
  • Longmont United Hospital
    Longmont, Colorado 80501, United States
  • Rocky Mountain Cancer Centers-Longmont
    Longmont, Colorado 80501, United States
  • Parker Adventist Hospital
    Parker, Colorado 80138, United States
  • Rocky Mountain Cancer Centers-Parker
    Parker, Colorado 80138, United States
  • Saint Mary Corwin Medical Center
    Pueblo, Colorado 81004, United States
  • Rocky Mountain Cancer Centers - Pueblo
    Pueblo, Colorado 81008, United States
  • Rocky Mountain Cancer Centers-Thornton
    Thornton, Colorado 80260, United States
  • Broward Health Medical Center
    Fort Lauderdale, Florida 33316, United States
  • University Cancer and Blood Center LLC
    Athens, Georgia 30607, United States
  • Dekalb Medical Center
    Decatur, Georgia 30033, United States
  • Saint Alphonsus Cancer Care Center-Boise
    Boise, Idaho 83706, United States
  • Saint Luke's Cancer Institute - Boise
    Boise, Idaho 83712, United States
  • Saint Alphonsus Cancer Care Center-Caldwell
    Caldwell, Idaho 83605, United States
  • Kootenai Health - Coeur d'Alene
    Coeur d'Alene, Idaho 83814, United States
  • Walter Knox Memorial Hospital
    Emmett, Idaho 83617, United States
  • Saint Luke's Cancer Institute - Fruitland
    Fruitland, Idaho 83619, United States
  • Idaho Urologic Institute-Meridian
    Meridian, Idaho 83642, United States
  • Saint Luke's Cancer Institute - Meridian
    Meridian, Idaho 83642, United States
  • Saint Alphonsus Medical Center-Nampa
    Nampa, Idaho 83686, United States
  • Saint Luke's Cancer Institute - Nampa
    Nampa, Idaho 83686, United States
  • Kootenai Clinic Cancer Services - Post Falls
    Post Falls, Idaho 83854, United States
  • Kootenai Cancer Clinic
    Sandpoint, Idaho 83864, United States
  • Saint Luke's Cancer Institute - Twin Falls
    Twin Falls, Idaho 83301, United States
  • Rush - Copley Medical Center
    Aurora, Illinois 60504, United States
  • Illinois CancerCare-Bloomington
    Bloomington, Illinois 61704, United States
  • Illinois CancerCare-Canton
    Canton, Illinois 61520, United States
  • Memorial Hospital of Carbondale
    Carbondale, Illinois 62902, United States
  • SIH Cancer Institute
    Carterville, Illinois 62918, United States
  • Illinois CancerCare-Carthage
    Carthage, Illinois 62321, United States
  • Centralia Oncology Clinic
    Centralia, Illinois 62801, United States
  • Carle on Vermilion
    Danville, Illinois 61832, United States
  • Cancer Care Specialists of Illinois - Decatur
    Decatur, Illinois 62526, United States
  • Decatur Memorial Hospital
    Decatur, Illinois 62526, United States
  • Carle Physician Group-Effingham
    Effingham, Illinois 62401, United States
  • Crossroads Cancer Center
    Effingham, Illinois 62401, United States
  • Illinois CancerCare-Eureka
    Eureka, Illinois 61530, United States
  • NorthShore University HealthSystem-Evanston Hospital
    Evanston, Illinois 60201, United States
  • Illinois CancerCare-Galesburg
    Galesburg, Illinois 61401, United States
  • Western Illinois Cancer Treatment Center
    Galesburg, Illinois 61401, United States
  • NorthShore University HealthSystem-Glenbrook Hospital
    Glenview, Illinois 60026, United States
  • NorthShore University HealthSystem-Highland Park Hospital
    Highland Park, Illinois 60035, United States
  • Edward Hines Jr VA Hospital
    Hines, Illinois 60141, United States
  • Illinois CancerCare-Kewanee Clinic
    Kewanee, Illinois 61443, United States
  • Illinois CancerCare-Macomb
    Macomb, Illinois 61455, United States
  • Carle Physician Group-Mattoon/Charleston
    Mattoon, Illinois 61938, United States
  • Trinity Medical Center
    Moline, Illinois 61265, United States
  • Cancer Care Center of O'Fallon
    O'Fallon, Illinois 62269, United States
  • Illinois CancerCare-Ottawa Clinic
    Ottawa, Illinois 61350, United States
  • Illinois CancerCare-Pekin
    Pekin, Illinois 61554, United States
  • Illinois CancerCare-Peoria
    Peoria, Illinois 61615, United States
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61636, United States
  • Illinois CancerCare-Peru
    Peru, Illinois 61354, United States
  • Valley Radiation Oncology
    Peru, Illinois 61354, United States
  • Illinois CancerCare-Princeton
    Princeton, Illinois 61356, United States
  • SwedishAmerican Regional Cancer Center/ACT
    Rockford, Illinois 61114, United States
  • North Shore Medical Center
    Skokie, Illinois 60076, United States
  • Southern Illinois University School of Medicine
    Springfield, Illinois 62702, United States
  • Springfield Clinic
    Springfield, Illinois 62702, United States
  • Memorial Medical Center
    Springfield, Illinois 62781, United States
  • Southwest Illinois Health Services LLP
    Swansea, Illinois 62226, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • The Carle Foundation Hospital
    Urbana, Illinois 61801, United States
  • Rush-Copley Healthcare Center
    Yorkville, Illinois 60560, United States
  • Parkview Hospital Randallia
    Fort Wayne, Indiana 46805, United States
  • Parkview Regional Medical Center
    Fort Wayne, Indiana 46845, United States
  • Reid Health
    Richmond, Indiana 47374, United States
  • Mary Greeley Medical Center
    Ames, Iowa 50010, United States
  • McFarland Clinic PC - Ames
    Ames, Iowa 50010, United States
  • McFarland Clinic PC-Boone
    Boone, Iowa 50036, United States
  • Medical Oncology and Hematology Associates-West Des Moines
    Clive, Iowa 50325, United States
  • Mercy Cancer Center-West Lakes
    Clive, Iowa 50325, United States
  • Alegent Health Mercy Hospital
    Council Bluffs, Iowa 51503, United States
  • Greater Regional Medical Center
    Creston, Iowa 50801, United States
  • Iowa Methodist Medical Center
    Des Moines, Iowa 50309, United States
  • Medical Oncology and Hematology Associates-Des Moines
    Des Moines, Iowa 50309, United States
  • Broadlawns Medical Center
    Des Moines, Iowa 50314, United States
  • Medical Oncology and Hematology Associates-Laurel
    Des Moines, Iowa 50314, United States
  • Mercy Medical Center - Des Moines
    Des Moines, Iowa 50314, United States
  • Iowa Lutheran Hospital
    Des Moines, Iowa 50316, United States
  • McFarland Clinic PC-Trinity Cancer Center
    Fort Dodge, Iowa 50501, United States

Showing the first 100 of 468 sites. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in May 2022, 48 months.

Results were first posted in Feb 2023, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2018
First posted
Mar 19, 2018
StartActual
May 7, 2018
Primary completionActual
May 9, 2022
CompletionActual
Dec 21, 2022
Results first posted
Feb 8, 2023
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03468985
Responsible party
Sponsor
First posted
Mar 19, 2018
Start date
May 7, 2018
Primary completion
May 9, 2022
Completion
Dec 21, 2022
Results posted
Feb 8, 2023
Last update
Oct 17, 2023

Study contacts

Joel W Neal
principal investigator · ECOG-ACRIN Cancer Research Group

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabozantinib · Ipilimumab

Start the discussion